Results 11 to 20 of about 73,909 (338)

Molecular pathways driving omeprazole nephrotoxicity

Redox Biology, 2020
Omeprazole, a proton pump inhibitor used to treat peptic ulcer and gastroesophageal reflux disease, has been associated to chronic kidney disease and acute interstitial nephritis. However, whether omeprazole is toxic to renal cells is unknown. Omeprazole
Miguel Fontecha-Barriuso, Diego Martín-Sanchez, Julio M. Martinez-Moreno, Daniela Cardenas-Villacres, Susana Carrasco, Maria D. Sanchez-Niño, Marta Ruiz-Ortega, Alberto Ortiz, Ana B. Sanz   +8 more
doaj   +2 more sources

Omeprazole Treatment Enhances Nitrogen Use Efficiency Through Increased Nitrogen Uptake and Assimilation in Corn

Frontiers in Plant Science, 2019
Omeprazole is a selective proton pump inhibitor in humans that inhibits the H+/K+-ATPase of gastric parietal cells. Omeprazole has been recently shown to act as a plant growth regulator and enhancer of salt stress tolerance.
Michael James Van Oosten, Emilia Dell’Aversana, Alessandra Ruggiero, Valerio Cirillo, Yves Gibon, Pasqualina Woodrow, Albino Maggio, Petronia Carillo   +7 more
doaj   +2 more sources

Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis. [PDF]

PLoS ONE, 2014
Benzimidazole drugs lansoprazole and omeprazole are used for treatment of various gastrointestinal pathologies. Both compounds cause drug-drug interactions because they activate aryl hydrocarbon receptor and induce CYP1A genes.
Aneta Novotna, Zdenek Dvorak
doaj   +2 more sources

Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection [PDF]

, 1998
In this randomized, multicenter trial, we evaluated the effectiveness and side effect profile of a modified omeprazole-based triple therapy to cure Helicobacter pylori infection.
Bayerdörffer, Ekkehard, Bolle, Karl-Heinz, Höchter, Wilhelm, Klann, Hermann, Krämer, Walter, Lehn, Norbert, Meining, Alexander, Miehlke, Stephan, Simon, Thomas, Sommer, Albrecht, Stolte, Manfred, Weingart, Josef   +11 more
core   +3 more sources

Omeprazole exacerbates intervertebral disc degeneration through Caspase-3 mediated apoptosis of nucleus pulposus cells: a Mendelian randomization, network toxicology, and in vitro experimental study [PDF]

Journal of Orthopaedic Surgery and Research
Objective To investigate the causal correlation and toxicological mechanisms of omeprazole in intervertebral disc degeneration (IVDD), alongside a particular emphasis on Caspase-3 (CASP3) mediated apoptosis of nucleus pulposus cells (NPCs).
Yuchao Jia, Haifan Zhao, Shengbo Huang, Baoshan Xu   +3 more
doaj   +2 more sources

Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study [PDF]

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 10, October 2025.
ABSTRACT Purpose Clopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains controversial.
Aljoharah M. Algabbani, Sumaya N. Almohareb, Adel A. Alrwisan   +2 more
wiley   +2 more sources

Omeprazole [PDF]

Alimentary Pharmacology & Therapeutics, 1991
SUMMARYOmeprazole is a potent and effective antisecretory drug. Benefits in gastric and duodenal ulceration nevertheless seem marginal because standard treatments are very effective. More obvious advantages are discernible in oesophageal reflux disease where more profound acid inhibition may be needed to obtain symptom relief.
John A. Oates, Alastair J.J. Wood, Paul N. Maton   +2 more
  +9 more sources

Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation

Bioscience Reports, 2021
The curative effect for patients with advanced gastric cancer is still unsatisfactory. Proton pump inhibitors could be a promising treatment strategy that could sensitize gastric cancer cells to antitumor drugs further; however, the underlying molecular ...
S. Feng, G. Qiu, Lihong Yang, Lihua Feng, Xin Fan, Fang Ren, Kaida Huang, Yide Chen   +7 more
semanticscholar   +1 more source

Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC

Clinical Cancer Research, 2021
Purpose: Fatty acid synthase (FASN) is overexpressed in 70% of operable triple-negative breast cancer (TNBC) and is associated with poor prognosis. Proton pump inhibitors selectively inhibit FASN activity and induce apoptosis in TNBC cell lines. Patients
S. Sardesai, Alexandra Thomas, C. Gallagher, F. Lynce, Y. Ottaviano, T. Ballinger, B. Schneider, A. Storniolo, Amber Bauchle, S. Althouse, S. Perkins, A. Masters, R. Stratford, Zizheng Dong, Jing-Yuan Liu, Jian-Ting Zhang, K. Miller   +16 more
semanticscholar   +1 more source

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women

Clinical and Translational Science, 2022
This study evaluated the effect of repeated doses of elagolix on the pharmacokinetics (PK) of omeprazole and its metabolites in healthy premenopausal female subjects. Adult premenopausal female subjects (N = 20) received a single oral dose of omeprazole (
Ahmed Nader, Nael M. Mostafa, Elaine Kim, Mohamad Shebley   +3 more
doaj   +1 more source